Researchers at the Weizmann Institute engineered tobacco plants to produce five psychedelic compounds—psilocybin, psilocin, DMT, and two others—using a genetic technique that doesn't permanently alter the plant's DNA. Growing these drugs in greenhouses would be cheaper and more sustainable than chemical synthesis or wild harvesting, which threatens plant and fungal populations. The work, published in Science Advances, demonstrates a 'pharming' approach already used for other pharmaceutical proteins since 2012. The researchers deliberately avoided permanent genetic modification to prevent seeds from being distributed as recreational drugs.